Sun Pharmaceutical Industries Ltd.
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
www.sunpharma.com
CIN : L24230GJ1993PLC019050

August 8, 2017

**National Stock Exchange of India Ltd,**
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
**NSE Code – SUNPHARMA**

**BSE Ltd,**
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
**BSE Code– 524715**

**Sub:** Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

This is to inform you that one of the wholly owned subsidiaries of the Company has agreed to acquire by way of allotment to it, 203,135 Series A Preferred Stock (equivalent to 15.91% fully diluted equity stake on conversion) of Krystal Biotech Inc., United States of America, a biopharmaceutical company using gene therapy to develop treatments for patients suffering from rare debilitating disorders.

The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as per 'Annexure A'.

This is for your information and record.

Yours faithfully,
**For Sun Pharmaceutical Industries Limited,**

**Ashok I Bhuta**
**Compliance Officer**

Enclosures:
1. Annexure A

Sun Pharmaceutical Industries Ltd.
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
www.sunpharma.com
CIN : L24230GJ1993PLC019050

SUN PHARMA

**Annexure A**

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

| | |
|---|---|
| a) Name of the target entity, details in brief such as size, turnover etc.; | **i) Name of the Target :**<br>"Krystal Biotech Inc." (Target)<br><br>**ii) Details of the Target:**<br>Biopharmaceutical company using gene therapy to develop treatments for patients suffering from rare debilitating disorders.<br><br>**2017 Sales**: Since the target company has been incorporated on March 31, 2017, there are no sales. |
| b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length"; | **Krystal Biotech Inc., is an independent company** and the promoter/ promoter group/ group companies of Sun Pharmaceutical Industries Limited have no interest in the Target, so the acquisition would not fall within related party transaction(s). |
| c) Industry to which the entity being acquired belongs; | Pharmaceuticals |
| d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); | Investment in Pharmaceutical Company |
| e) Brief details of any governmental or regulatory approvals required for the acquisition; | No approvals are required |
| f) Indicative time period for completion of the acquisition; | August 09, 2017 |
| g) Nature of consideration - whether cash consideration or share swap and details of the same; | Cash consideration of USD 7 million would be paid for acquisition of Shares |

| | |
|---|---|
| h) Cost of acquisition or the price at which the shares are acquired; | Shares are being acquired at USD 34.46 per share |
| i) Percentage of shareholding / control acquired and / or number of shares acquired; | 203,135 Series A Preferred Stock (equivalent to 15.91% fully diluted equity stake on conversion) of Krystal Biotech Inc., & which are convertible to one common share each per each Preferred Stock) are being acquired by way of allotment. |
| j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); | **Brief background:**<br>Biopharmaceutical company using gene therapy to develop treatments for patients suffering from rare debilitating disorders<br><br>**Date of incorporation:** March 31, 2017<br><br>**Turnover of last 3 years:** Not Applicable, since the target company has been incorporated on March 31, 2017.<br><br>**Line of business:** Pharmaceuticals<br><br>**Country in which the acquired entity has presence:** United States of America |

**For Sun Pharmaceutical Industries Limited,**

**Ashok I Bhuta**
**Compliance Officer**